Anti-inflammatory therapy targeting interleukin IL-1β reduces the risk of recurrent cardiovascular events in patients with previous myocardial infarcts.22 The TNF-α levels have been reported to be elevated in the serum of patients with STEMI,23 a finding consistent with ours. The gene discussed is IL1B; the disease is myocardial infarction.